Following up on my series of posts based on Dr Chris Bohl’s work at Sekisui Xenotech, in this post I invite you to take a look at the work he has published, together with Dr Christopher Seib, Maciej Czerwinski, Zell Woodworth and David Buckley, Ph.D., illustrating the characterization of isolated human liver lysosomes, and validating them as test systems for in vitro assessment of catabolic stability of biologics drugs entering the cell by the endosomal–lysosomal pathway.

In a few forthcoming posts, I’d like to share several short articles published by Dr Chris Bohl of Sekisui Xenotech, a technical expert in the field of ADME-Tox tools and applications. I feel they may be of special interest to researchers working in the field of ADME-Tox studies.

Today, we’ll take a look at compounds that exhibit high metabolic stability in hepatocytes and subcellular fractions (S9, microsomes and cytosol), as these can be a challenge for ADME scientists.

Sekisui Xenotech’s Research BioBank provides you with normal and diseased human liver tissue samples for scientific investigation. Tissues are collected with the initial intent for transplant, thus making them perfect candidates to advance basic medical science and contribute to the development of new treatments.

The care taken to preserve viability of the tissue intended for transplantation distinguishes these Research Biobank specimens from samples collected at a typical post-mortem, usually compromised by several hours of a warm ischemia. So what are the other benefits of the biobank?

Sekisui XenoTech now offers human liver tissue microarrays (TMA) and a microsomal pool for studying and developing new treatments for fatty liver disease (FLD). The microsomes and arrays feature non-alcoholic steatohepatitis (NASH) and other liver tissue from the company’s Research Biobank . The initiative is part of Sekisui XenoTech’s ongoing commitment to furthering knowledge of hepatic diseases.

“Fatty liver disease is a highly pervasive condition that has a very significant impact on the health of modern society. We are supporting hepatology researchers with these collections of high-quality human tissues to advance basic knowledge of FLD and to develop new treatments for the illness,” explained Maciej Czerwinski, Ph.D., Sekisui XenoTech Director of Consulting who led the effort to establish the company’s research Biobank and develop the microarrays.